A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Tesla stock dropped in the DeepSeek sell off, but nothing like Nvidia stock. Deutsche Bank, however, believes investors ...

Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...

The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗的耐药性相关联[1]。研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...